Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 43.911
Filter
2.
Pediatr Allergy Immunol ; 35(5): e14147, 2024 May.
Article in English | MEDLINE | ID: mdl-38773751

ABSTRACT

BACKGROUND: Inflammatory bowel disease (IBD) and allergic diseases possess similar genetic backgrounds and pathogenesis. Observational studies have shown a correlation, but the exact direction of cause and effect remains unclear. The aim of this Mendelian randomization (MR) study is to assess bidirectional causality between inflammatory bowel disease and allergic diseases. METHOD: We comprehensively analyzed the causal relationship between inflammatory bowel disease (IBD), Crohn's disease (CD), ulcerative colitis (UC) and allergic disease (asthma, Hay fever, and eczema) as a whole, allergic conjunctivitis (AC), atopic dermatitis (AD), allergic asthma (AAS), and allergic rhinitis (AR) by performing a bidirectional Mendelian randomization study using summary-level data from genome-wide association studies. The analysis results mainly came from the random-effects model of inverse variance weighted (IVW-RE). In addition, multivariate Mendelian randomization (MVMR) analysis was conducted to adjust the effect of body mass index (BMI) on the instrumental variables. RESULTS: The IVW-RE method revealed that IBD genetically increased the risk of allergic disease as a whole (OR = 1.03, 95% CI = 1.01-1.04, fdr.p = .015), AC (OR = 1.04, 95% CI = 1.01-1.06, fdr.p = .011), and AD (OR = 1.06, 95% CI = 1.02-1.09, fdr.p = .004). Subgroup analysis further confirmed that CD increased the risk of allergic disease as a whole (OR = 1.02, 95% CI = 1.00-1.03, fdr.p = .031), AC (OR = 1.03, 95% CI = 1.01-1.05, fdr.p = .012), AD (OR = 1.06, 95% CI = 1.02-1.09, fdr.p = 2E-05), AAS (OR = 1.05, 95% CI = 1.02-1.08, fdr.p = .002) and AR (OR = 1.03, 95% CI = 1.00-1.07, fdr.p = .025), UC increased the risk of AAS (OR = 1.02, 95% CI = 0.98-1.07, fdr.p = .038). MVMR results showed that after taking BMI as secondary exposure, the causal effects of IBD on AC, IBD on AD, CD on allergic disease as a whole, CD on AC, CD on AD, CD on AAS, and CD on AR were still statistically significant. No significant association was observed in the reverse MR analysis. CONCLUSION: This Mendelian randomized study demonstrated that IBD is a risk factor for allergic diseases, which is largely attributed to its subtype CD increasing the risk of AC, AD, ASS, and AR. Further investigations are needed to explore the causal relationship between allergic diseases and IBD.


Subject(s)
Genetic Predisposition to Disease , Genome-Wide Association Study , Hypersensitivity , Inflammatory Bowel Diseases , Mendelian Randomization Analysis , Humans , Inflammatory Bowel Diseases/genetics , Inflammatory Bowel Diseases/epidemiology , Hypersensitivity/genetics , Hypersensitivity/epidemiology , Polymorphism, Single Nucleotide , Asthma/genetics , Asthma/epidemiology , Crohn Disease/genetics , Crohn Disease/epidemiology , Dermatitis, Atopic/genetics , Dermatitis, Atopic/epidemiology , Colitis, Ulcerative/genetics , Colitis, Ulcerative/epidemiology , Risk Factors , Body Mass Index
3.
Arerugi ; 73(3): 268-278, 2024.
Article in Japanese | MEDLINE | ID: mdl-38749711

ABSTRACT

BACKGROUND: In 2022, the "New Capitalism Grand Design and Implementation Plan" was adopted in Japan, emphasizing the promotion and environmental development of startups. Given this context, an investigation into the startup and investment landscape in the allergy sector, both domestically and internationally, becomes imperative. METHODS: We analyzed 156 allergy-related startups from Japan, the US, and Europe from 2010 to 2021. Data on corporate information and investment trends were extracted from databases and VC websites. RESULTS: The total investment reached approximately 7.2 billion USD, with a ratio of 20:6:1 for the US, Europe, and Japan, respectively. The US showed a decline post its peak from 2016-2018, while Europe and Japan experienced growth. Notably, the US primarily invested in biopharmaceuticals for atopic dermatitis and food allergies, Europe in asthma-related apps, and Japan in healthcare apps and cross-border startups. DISCUSSION AND CONCLUSION: While Japan's investment environment in the allergy sector remains in its nascent stages and has room for development, the US and Europe are evidently ahead. Considering the rise of startups and funding limitations in Japan, external funding from regions like the US becomes a potential avenue. These findings are anticipated to contribute to the strategic activation of startups in allergy research and development.


Subject(s)
Allergy and Immunology , Humans , Allergy and Immunology/economics , Hypersensitivity/therapy , Hypersensitivity/immunology , Japan , Investments , Europe , United States
4.
Sci Rep ; 14(1): 10694, 2024 05 10.
Article in English | MEDLINE | ID: mdl-38724620

ABSTRACT

This study investigated the potential associations between allergic diseases (asthma, allergic rhinitis, and atopic dermatitis) and the development of primary open-angle glaucoma. We utilized authorized data from the Korean National Health Information Database (KNHID), which provides comprehensive medical claims data and information from the National Health Screening Program. We compared the baseline characteristics of subjects with and without allergic diseases and calculated the incidence and risk of glaucoma development. Cox proportional hazard regression analysis was used to determine the risk of glaucoma development in subjects with allergic diseases. A total of 171,129 subjects aged 20-39 with or without allergic diseases who underwent a general health examination between 2009 and 2015 were included. Subjects with allergic diseases exhibited a higher incidence of glaucoma compared to the control group. The hazard ratio (HR) of glaucoma onset was 1.49 and 1.39 in subjects with at least one allergic disease before and after adjusting for potential confounding factors, respectively. Among allergic diseases, atopic dermatitis showed the highest risk for glaucoma development (aHR 1.73) after adjusting for confounders. Allergic rhinitis showed an increased risk for incident glaucoma after adjustment (aHR 1.38). Asthma showed the lowest but still increased risk for glaucoma (aHR 1.22). The associations were consistent in all subgroup analyses stratified by sex, smoking, drinking, exercise, diabetes, hypertension, dyslipidemia, or history of steroid. In conclusion, allergic diseases are associated with increased risk of glaucoma development. Among allergic diseases, atopic dermatitis showed the highest risk for glaucoma development followed by allergic rhinitis and asthma.


Subject(s)
Glaucoma, Open-Angle , Humans , Glaucoma, Open-Angle/epidemiology , Male , Female , Adult , Republic of Korea/epidemiology , Young Adult , Risk Factors , Incidence , Cohort Studies , Rhinitis, Allergic/epidemiology , Dermatitis, Atopic/epidemiology , Asthma/epidemiology , Asthma/complications , Hypersensitivity/epidemiology , Hypersensitivity/complications , Proportional Hazards Models
5.
Zhonghua Yu Fang Yi Xue Za Zhi ; 58(5): 711-718, 2024 May 06.
Article in Chinese | MEDLINE | ID: mdl-38715514

ABSTRACT

The human body, as a highly complex ecosystem, harbors diverse microbial communities, with major factors triggering allergic reactions encompassing the skin microbiome and fungi. The global diversity of fungi is estimated to range from approximately 600 000 to 1 million species, and theoretically, IgE-mediated sensitization may occur to any fungal species. As of now, the World Health Organization/IUIS official database records 113 fungal allergens originating from 30 different fungi species, covering 42 allergen families. Regarding the skin microbiome, 14 distinct Malassezia allergens have been identified, all derived from three different Malassezia fungi species--M. furfur, M. sympodialis, and M. globosa. The conditions of patients with these allergies are exceptionally complex. This article extensively discusses the latest research advancements and clinical applications related to skin microbiome and fungal allergies from the European Academy of Allergy and Clinical Immunology (EAACI) publication, "Molecular Allergology User's Guide 2.0". Additionally, it compiles information on the sources of fungal allergens, characteristics of allergen component protein families, clinical relevance, and management strategies, both domestically and internationally. The aim is to enhance the profound understanding of allergen components among relevant professionals. Through the application of advanced allergen component diagnostic techniques, the goal is to achieve precise diagnosis and treatment of fungal allergy patients and explore the mechanisms underlying fungal sensitization and pathogenesis, laying the foundation for studying the fungal allergen protein sensitization spectrum in the Chinese population.


Subject(s)
Allergens , Fungi , Hypersensitivity , Microbiota , Allergens/immunology , Humans , Fungi/immunology , Hypersensitivity/diagnosis , Fungal Proteins/immunology , Skin/microbiology , Malassezia/immunology
6.
J Ethnopharmacol ; 331: 118330, 2024 Sep 15.
Article in English | MEDLINE | ID: mdl-38740109

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Chromolaenaodorata (L.) R.M. King & H. Rob, a perennial herb, has been traditionally utilized as a herbal remedy for treating leech bites, soft tissue wounds, burn wounds, skin infections, and dento-alveolitis in tropical and subtropical regions. AIM OF THE STUDY: The present study was to analyze the active fraction of C. odorata ethanol extract and investigate its hemostatic, anti-inflammatory, wound healing, and antimicrobial properties. Additionally, the safety of the active fraction as an external preparation was assessed through skin irritation and allergy tests. MATERIALS AND METHODS: The leaves and stems of C. odorata were initially extracted with ethanol, followed by purification through AB-8 macroporous adsorption resin column chromatography to yield different fractions. These fractions were then screened for hemostatic activity in mice and rabbits to identify the active fraction. Subsequently, the hemostatic effect of the active fraction was assessed through the bleeding time of the rabbit ear artery in vivo and the coagulant time of rabbit blood in vitro. The anti-inflammatory activity of the active fraction was tested on mice ear edema induced by xylene and rat paw edema induced by carrageenin. Furthermore, the active fraction's promotion effect on wound healing was evaluated using a rat skin injury model, and skin safety tests were conducted on rabbits and guinea pigs. Lastly, antimicrobial activities against two Gram-positive bacteria (G+, Staphylococcus aureus and S. epidermidis) and three Gram-negative bacteria (G-, Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa) were determined using the plate dilution method. RESULTS: The ethanol extract of C. odorata leaves and stems was fractionated into 30%, 60%, and 90% ethanol eluate fractions. These fractions demonstrated hemostatic activity, with the 30% ethanol eluate fraction (30% EEF) showing the strongest effect, significantly reducing bleeding time (P < 0.05). A concentration of 1.0 g/mL of the 30% EEF accelerated cutaneous wound healing in rats on the 3rd, 6th, and 9th day post-operation, with the healing effect increasing over time. No irritation or allergy reactions were observed in rabbits and guinea pigs exposed to the 30% EEF. Additionally, the 30% EEF exhibited mild inhibitory effect on mice ear and rat paw edema, as well as antimicrobial activity against tested bacteria, with varying minimal inhibitory concentration (MIC) values. CONCLUSIONS: The 30% EEF demonstrated a clear hemostatic effect on rabbit bleeding time, a slight inhibitory effect on mice ear edema and rat paw edema, significant wound healing activity in rats, and no observed irritation or allergic reactions. Antibacterial activity was observed against certain clinically isolated bacteria, particularly the G- bacteria. This study lays the groundwork for the potential development and application of C. odorata in wound treatment.


Subject(s)
Anti-Inflammatory Agents , Chromolaena , Edema , Ethanol , Hemostatics , Plant Extracts , Wound Healing , Animals , Rabbits , Wound Healing/drug effects , Plant Extracts/pharmacology , Plant Extracts/chemistry , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/isolation & purification , Mice , Male , Hemostatics/pharmacology , Ethanol/chemistry , Chromolaena/chemistry , Edema/drug therapy , Edema/chemically induced , Rats , Skin/drug effects , Female , Anti-Infective Agents/pharmacology , Anti-Infective Agents/isolation & purification , Plant Leaves/chemistry , Hypersensitivity/drug therapy , Xylenes , Plant Stems/chemistry
8.
BMC Genomics ; 25(1): 503, 2024 May 22.
Article in English | MEDLINE | ID: mdl-38773393

ABSTRACT

BACKGROUND: While numerous allergy-related biomarkers and targeted treatment strategies have been developed and employed, there are still signifcant limitations and challenges in the early diagnosis and targeted treatment for allegic diseases. Our study aims to identify circulating proteins causally associated with allergic disease-related traits through Mendelian randomization (MR)-based analytical framework. METHODS: Large-scale cis-MR was employed to estimate the effects of thousands of plasma proteins on five main allergic diseases. Additional analyses including MR Steiger analyzing and Bayesian colocalisation, were performed to test the robustness of the associations; These findings were further validated utilizing meta-analytical methods in the replication analysis. Both proteome- and transcriptome-wide association studies approach was applied, and then, a protein-protein interaction was conducted to examine the interplay between the identified proteins and the targets of existing medications. RESULTS: Eleven plasma proteins were identified with links to atopic asthma (AA), atopic dermatitis (AD), and allergic rhinitis (AR). Subsequently, these proteins were classified into four distinct target groups, with a focus on tier 1 and 2 targets due to their higher potential to become drug targets. MR analysis and extra validation revealed STAT6 and TNFRSF6B to be Tier 1 and IL1RL2 and IL6R to be Tier 2 proteins with the potential for AA treatment. Two Tier 1 proteins, CRAT and TNFRSF6B, and five Tier 2 proteins, ERBB3, IL6R, MMP12, ICAM1, and IL1RL2, were linked to AD, and three Tier 2 proteins, MANF, STAT6, and TNFSF8, to AR. CONCLUSION: Eleven Tier 1 and 2 protein targets that are promising drug target candidates were identified for AA, AD, and AR, which influence the development of allergic diseases and expose new diagnostic and therapeutic targets.


Subject(s)
Biomarkers , Blood Proteins , Hypersensitivity , Mendelian Randomization Analysis , Proteomics , Humans , Proteomics/methods , Biomarkers/blood , Blood Proteins/genetics , Blood Proteins/metabolism , Blood Proteins/analysis , Hypersensitivity/genetics , Hypersensitivity/blood , Bayes Theorem , Genome-Wide Association Study
9.
Am J Reprod Immunol ; 91(5): e13865, 2024 May.
Article in English | MEDLINE | ID: mdl-38775338

ABSTRACT

INTRODUCTION: Seminal plasma hypersensitivity (SPH) is a rare and often misdiagnosed condition characterized by local and/or systemic reactions to seminal plasma proteins following exposure to semen. We aimed to summarize key symptomatology, diagnostic features, and management options for SPH. METHODS: The databases PubMed, EMBASE, Web of Science, Google Scholar, and Cochrane Review were searched with key words "seminal plasma hypersensitivity" and "seminal fluid allergy" through September 2023. Exclusion criteria included non-English articles, in vitro studies, publication before 1990, duplicates, and articles with no clinical relevance to SPH in women. RESULTS: The search yielded 53 articles for review. Of these, 60.5% described systemic SPH and 39.5% described localized. CONCLUSION: Diagnosis of SPH relies on a thorough patient history and confirmatory skin prick testing. The use of IgE assays is controversial and less accurate for cases of localized SPH. Knowledge of disease immunopathology, systemic versus localized symptom presentation, patient preference, and desire to conceive should guide management options. Artificial insemination has the potential for severe adverse reactions in systemic SPH so necessitates extra procedural precautions. SPH does not appear to impair fertility. Additional research on specific allergens implicated in SPH can aid in the development of more targeted immunotherapy approaches with improved safety and efficacy.


Subject(s)
Hypersensitivity , Semen , Humans , Male , Allergens/immunology , Hypersensitivity/diagnosis , Hypersensitivity/therapy , Hypersensitivity/immunology , Immunoglobulin E/immunology , Immunoglobulin E/blood , Insemination, Artificial , Semen/immunology , Seminal Plasma Proteins/immunology , Skin Tests , Female
11.
Curr Allergy Asthma Rep ; 24(6): 317-322, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38776041

ABSTRACT

PURPOSE OF REVIEW: This review aims to deliver a comprehensive report of the most recent knowledge on diagnosing allergic dermatoses in skin of color (SOC) patients. RECENT FINDINGS: Allergic dermatoses can affect populations of all backgrounds. However, racial/ethnic variations in epidemiology, clinical features, and associated allergens have been reported. Nuances in the approach to diagnosis, including the assessment of erythema and interpretation of patch tests, are important considerations when treating patients with SOC. In this review, we outline various manifestations of allergic dermatoses in SOC with a focus on important clinical presentations and diagnostic tools, aiming to support clinicians in accurate recognition of diseases, thereby opening avenues to improve outcomes across diverse skin types.


Subject(s)
Skin Pigmentation , Humans , Allergens/immunology , Hypersensitivity/diagnosis , Hypersensitivity/immunology , Skin Diseases/diagnosis , Skin/pathology , Skin/immunology , Patch Tests
12.
Int Immunopharmacol ; 134: 111825, 2024 Jun 15.
Article in English | MEDLINE | ID: mdl-38723368

ABSTRACT

In recent decades, allergic diseases subsequent from an IgE-mediated response to specific allergens have become a progressively public chronic disease worldwide. They have shaped an important medical and socio-economic burden. A significant proportion of allergic disorders are branded via a form 2 immune response relating Th2 cells, type 2 natural lymphoid cells, mast cells and eosinophils. Interleukin-21 (IL-21) is a participant of the type-I cytokine family manufactured through numerous subsets of stimulated CD4+ T cells and uses controlling properties on a diversity of immune cells. Increasingly, experimental sign suggests a character for IL-21 in the pathogenesis of numerous allergic disorders. The purpose of this review is to discuss the biological properties of IL-21 and to summaries current developments in its role in the regulation of allergic disorders.


Subject(s)
Hypersensitivity , Interleukins , Humans , Interleukins/immunology , Interleukins/metabolism , Animals , Hypersensitivity/immunology , Th2 Cells/immunology , Mast Cells/immunology
13.
Curr Allergy Asthma Rep ; 24(6): 323-330, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38733510

ABSTRACT

PURPOSE OF REVIEW: This paper explores how environmental factors influence allergic skin diseases, including atopic dermatitis (AD), contact dermatitis (CD), urticaria, angioedema, and reactions to drugs and insect bites. RECENT FINDINGS: Research indicates a significant impact of environmental elements on allergic skin diseases. High air pollution levels exacerbate symptoms, while climate change contributes to increased skin barrier dysfunction, particularly affecting AD. Allergen prevalence is influenced by climate and pollution. Irritants, like those in detergents and cosmetics, play a major role in CD. Plants also contribute, causing various skin reactions. Understanding the interplay between environmental factors and allergic skin diseases is crucial for effective management. Physicians must address these factors to support patient well-being and promote skin health amidst environmental changes.


Subject(s)
Dermatitis, Atopic , Humans , Dermatitis, Atopic/immunology , Dermatitis, Atopic/etiology , Allergens/immunology , Environmental Exposure/adverse effects , Environment , Hypersensitivity/immunology , Climate Change , Skin Diseases/immunology , Skin Diseases/etiology , Air Pollution/adverse effects , Animals , Urticaria/immunology , Urticaria/etiology
14.
Int Immunopharmacol ; 134: 112256, 2024 Jun 15.
Article in English | MEDLINE | ID: mdl-38744172

ABSTRACT

The incidence of allergic reactions has risen steadily in recent years, prompting growing interest in the identification of efficacious and safe natural compounds that can prevent or treat allergic diseases. Phellodendron amurense Rupr. has long been applied as a treatment for allergic diseases, whose primary component is phellodendrine. However, the efficacy of phellodendrine as a treatment for allergic diseases remains to be assessed. Mast cells are the primary effectors of allergic reactions, which are not only activated by IgE-dependent pathway, but also by IgE-independent pathways via human MRGPRX2, rat counterpart MRGPRB3. As such, this study explored the effect and mechanism of phellodendrine through this family receptors in treating allergic diseases in vitro and in vivo. These analyses revealed that phellodendrine administration was sufficient to protect against C48/80-induced foot swelling and Evans blue exudation in mice, and suppressed C48/80-induced RBL-2H3 rat basophilic leukemia cells degranulation, and ß-HEX, HIS, IL-4, and TNF-α release. Moreover, phellodendrine could reduce the mRNA expression of MRGPRB3 and responsiveness of MRGPRX2 by altering its structure. It was able to decrease Ca2+ levels, phosphorylation levels of CaMK, PLCß1, PKC, ERK, JNK, p38, and p65, and inhibit the degradation of IκB-α. These analyses indicate that berberine inhibits the activation of PLC and downregulates the release of Ca2+ in the endoplasmic reticulum by altering the conformation of MRGPRB3/MRGPRX2 protein, thereby inhibiting the activation of PKC and subsequently inhibiting downstream MAPK and NF-κB signaling, ultimately suppressing allergic reactions. There may thus be further value in studies focused on developing phellodendrine as a novel anti-allergic drug.


Subject(s)
Cell Degranulation , Hypersensitivity , Mast Cells , Receptors, G-Protein-Coupled , Animals , Rats , Mast Cells/drug effects , Mast Cells/immunology , Cell Degranulation/drug effects , Mice , Humans , Hypersensitivity/drug therapy , Hypersensitivity/immunology , Receptors, G-Protein-Coupled/metabolism , Anti-Allergic Agents/pharmacology , Anti-Allergic Agents/therapeutic use , Cytokines/metabolism , p-Methoxy-N-methylphenethylamine , Male , Phellodendron/chemistry , Cell Line, Tumor , Nerve Tissue Proteins/metabolism , Nerve Tissue Proteins/genetics , Mice, Inbred BALB C , NF-kappa B/metabolism , Signal Transduction/drug effects , Receptors, Neuropeptide
15.
Med Clin North Am ; 108(4): 757-776, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38816116

ABSTRACT

Stinging insects are a frequent cause of local and systemic hypersensitivity reactions, including anaphylaxis. For those with a history of life-threatening anaphylaxis, venom immunotherapy is effective, safe, and can be life-saving. Arachnids are a much less common source of envenomation through bites or stings and are less likely to cause a hypersensitivity reaction. However, recognizing the clinical manifestations when they do present is important for accurate diagnosis and treatment, and, when indicated, consideration of other diagnoses.


Subject(s)
Anaphylaxis , Insect Bites and Stings , Humans , Insect Bites and Stings/complications , Anaphylaxis/therapy , Anaphylaxis/diagnosis , Anaphylaxis/etiology , Animals , Hypersensitivity/therapy , Hypersensitivity/diagnosis , Arthropod Venoms/immunology , Arthropod Venoms/adverse effects , Desensitization, Immunologic/methods , Venom Hypersensitivity
19.
Yakugaku Zasshi ; 144(5): 483-488, 2024.
Article in Japanese | MEDLINE | ID: mdl-38692921

ABSTRACT

Allergic diseases (e.g., food allergies) are a growing problem, with increasing numbers of individuals experiencing them worldwide. Congruently, the adverse reactions (e.g., anaphylaxis) associated with the administration of vaccines against emerging infectious diseases such as coronavirus disease 2019 (COVID-19) have become a familiar problem. Allergic diseases, which have a wide variety of symptoms, are difficult to prevent or cure; treatment is currently limited to therapeutic drugs or allergen immunotherapy. Therefore, elucidating new allergic regulatory factors that control the allergic (i.e., mast cell) responses is important. While investigating the regulatory mechanisms of the wide range of allergic responses of mast cells, we found that the affinity of allergens to immunoglobin E (IgE) regulates allergic inflammation through the differences in the secretory responses of mast cells and the types and interactions of the cells infiltrating the tissues. Here, we present our recent findings regarding the affinity of allergens to IgE in regulating allergic inflammation, heterogeneous secretory granules inducing diverse secretory responses, and mast cells interacting with neutrophils, thereby regulating the various allergic responses.


Subject(s)
Cell Communication , Hypersensitivity , Immunoglobulin E , Mast Cells , Neutrophils , Mast Cells/immunology , Humans , Hypersensitivity/immunology , Hypersensitivity/etiology , Immunoglobulin E/immunology , Neutrophils/immunology , Allergens/immunology , Animals , Food Hypersensitivity/immunology , Food Hypersensitivity/therapy , COVID-19/immunology , COVID-19/prevention & control
20.
Allergy Asthma Proc ; 45(3): 195-200, 2024 May 01.
Article in English | MEDLINE | ID: mdl-38755779

ABSTRACT

Introduction: Hymenoptera venom immunotherapy (VIT) is the only therapy that protects patients with Hymenoptera venom allergy by preventing systemic reactions after a new sting. Various extracts for VIT are available and used. VIT administration consists of an induction phase and a maintenance phase. Depot preparations of Hymenoptera VIT extracts are typically used for cluster and conventional protocols, and the maintenance phase. Many patients with Hymenoptera allergy need to achieve tolerance quickly because of the high risk of re-sting and possible anaphylaxis. Objective: Our study aimed to show the safety and efficacy of an accelerated regimen with depot preparations on aluminum hydroxide by using relatively high starting doses in a heterogeneous group of patients. Methods: The research focused on a group of patients with a history of severe systemic reactions to Hymenoptera stings, with the necessity of swift immunization due to high occupational risks. Aluminum hydroxide depot extracts either of Vepula species or Apis mellifera extracts were used. Results: The induction protocol was started with the highest concentration of depot venom extract of 100,000 standard quality unit and was well tolerated by 19 of 20 patients. Onne patient presented with a mild systemic reaction during the accelerated induction schedule, which was promptly treated with intravenous steroids and intramuscular H1 antihistamine; when switched to a conventional induction protocol, he had a similar reaction but finally reached maintenance with an H1-antagonist premedication. Conclusion: If validated, the accelerated induction protocol by using depot aluminum adsorbed extracts with the highest concentration of venom from the beginning could offer a streamlined and accessible treatment modality for patients diagnosed with anaphylaxis from bee and wasp venoms in need of rapid desensitization.


Subject(s)
Desensitization, Immunologic , Hymenoptera , Humans , Desensitization, Immunologic/methods , Desensitization, Immunologic/adverse effects , Animals , Adult , Male , Female , Middle Aged , Hymenoptera/immunology , Aluminum Hydroxide , Insect Bites and Stings/immunology , Insect Bites and Stings/therapy , Treatment Outcome , Young Adult , Allergens/immunology , Allergens/administration & dosage , Adolescent , Hypersensitivity/therapy , Hypersensitivity/immunology , Arthropod Venoms/immunology , Aged , Bee Venoms/immunology , Bee Venoms/administration & dosage , Bee Venoms/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...